Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
Zacks News
Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate
by Zacks Equity Research
Novovax (NVAX) announces plans to initiate clinical study to evaluate its coronavirus vaccine candidate in May, weeks ahead of schedule.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Top Sectors of Q1 & Their Winning Stocks
by Sanghamitra Saha
Inside the top-performing sectors of Q1 and their winning stocks.
Why Is Emergent Biosolutions (EBS) Down 23.6% Since Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IMV to Develop Vaccine Candidate Against COVID-19, Shares Up
by Zacks Equity Research
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.
Emergent (EBS) Begins Development of Treatments for COVID-19
by Zacks Equity Research
Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.
Emergent BioSolutions Collaborates for Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.
Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.
Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.
Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View
by Zacks Equity Research
Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.
AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
by Zacks Equity Research
AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.
Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer
by Zacks Equity Research
Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).
Catabasis (CATB) Partners with UK-Based Charity for DMD Study
by Zacks Equity Research
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib
by Zacks Equity Research
Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
by Zacks Equity Research
Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
EBS vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EBS vs. ILMN: Which Stock Is the Better Value Option?
Incyte's Application for Pemigatinib Gets EMA's Validation
by Zacks Equity Research
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
5 Top Value Picks to Counter Recent Stock Market Softness
by Nalak Das
The stable economic fundamentals of the United States have raised the possibility of the recent stock market volatility being a transitory phase and markets continuing their long-term uptrend.
Emergent Biosolutions (EBS) Down 4.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
EBS or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EBS vs. ILMN: Which Stock Is the Better Value Option?
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.
Emergent Biosolutions (EBS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 92.06% and 14.49%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?